Nintedanib and soft

Phase 2Small molecule

HHospices Civils de Lyon

Nintedanib and soft is one of 11 small molecule programs targeting Epistaxis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpistaxisActive, not recruiting

EpistaxisPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Epistaxis

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Approved

5 2

Avastin

BBio-Thera Solutions

Approved

1 3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Bactroban

PPadagis LLC

Approved

—5

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

1 6

Rhofade

KKenvue Brands

Phase 2

1 7

Nintedanib and soft

HHospices Civils de Lyon

Phase 2

1 8

Silver Nitrate

MMansoura University Hospital

Preclinical

1 9

Floseal

UUnity Health Toronto

Preclinical

2 10

Trichloroacetic Acid

IIndonesia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epistaxis1 trial

Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.

Completed·HHospices Civils de Lyon·Phase 2·NCT03954782·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nintedanib and soft. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nintedanib and soft compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nintedanib and soft. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHospices Civils de Lyon

Nintedanib and soft

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epistaxis1 trial

References

Drug Info

Quick Facts

Related News